TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

C Massard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.